Discovery of novel biomarkers in peripheral arterial disease/metabolic syndrome

niversity of Dundee (UK)0 个研究点目标入组 80 人开始时间: 2007年6月19日最近更新: 2017年7月24日

适应症

试验速览

暂无简介。

•For Phase 1 study subjects with PAD and type 2 diabetes will be included. PAD will be defined as patients with classical symptoms of intermittent claudication plus an Ankle brachial Blood Pressure Index (ABPI) of <0.9, the accepted cut off level for such a diagnosis.
•For Phase 2 study patients with short distance claudication (<200 yards) will be selected for the walking study, as their walking distances are more reproducible (i.e. using the standardized Gardner walking treadmill protocol no more than 25% variation from 2 consecutive treadmill tests performed at least a week apart during the screening period). Patients for this second study will be type 2 diabetic patients not receiving insulin.

•1. Contraindication to thiazolidinedione group of drugs
•2. Subjects taking sulphonylureas
•3. Subjects with cardiovascular disease event within last three months (such as Myocardial Infarction [MI], unstable angina and stroke)
•4. For Phase 2 study, subjects having more than 25% variation from 2 consecutive treadmill tests performed at least a week apart

发起方

niversity of Dundee (UK)